Brief: Seelos Therapeutics Announces Participation Of Acadia Healthcare In The Registration Directed Study Of SLS-002
13/09/2022 13:25
Sept 13 (Reuters) - Seelos Therapeutics Inc SEEL.O :
* SEELOS THERAPEUTICS ANNOUNCES THE PARTICIPATION OF ACADIA
HEALTHCARE IN THE REGISTRATION DIRECTED STUDY OF SLS-002
(INTRANASAL RACEMIC KETAMINE) FOR ACUTE SUICIDAL IDEATION AND
BEHAVIOR IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER
Source text for Eikon: ID:nPn1Bxb40a
Further company coverage: SEEL.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Seelos Therapeutics
See all newsBrief: Seelos Therapeutics Commences Chapter 11 Proceedings- Court Filing
Brief: Seelos Therapeutics Announces Notice Of Delisting From Nasdaq And Transfer Of Listing To Over-The-Counter Market
Brief: Seelos Announces Postponement Of Its Annual Meeting Of Stockholders
Brief: Seelos Therapeutics Announces 1-For-16 Reverse Stock Split
U.S. STOCKS ON THE MOVE-Copper miners, Visa, Bluebird bio